These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 30275538)

  • 21. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.
    Ma B; Duan X; Zhou Q; Liu J; Yang X; Zhang D; Yang S; Du Y; Li H; Su C
    J Cell Mol Med; 2019 Jul; 23(7):4514-4522. PubMed ID: 31090213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.
    Stanietsky N; Simic H; Arapovic J; Toporik A; Levy O; Novik A; Levine Z; Beiman M; Dassa L; Achdout H; Stern-Ginossar N; Tsukerman P; Jonjic S; Mandelboim O
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17858-63. PubMed ID: 19815499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
    Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
    J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
    Stamm H; Klingler F; Grossjohann EM; Muschhammer J; Vettorazzi E; Heuser M; Mock U; Thol F; Vohwinkel G; Latuske E; Bokemeyer C; Kischel R; Dos Santos C; Stienen S; Friedrich M; Lutteropp M; Nagorsen D; Wellbrock J; Fiedler W
    Oncogene; 2018 Sep; 37(39):5269-5280. PubMed ID: 29855615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.
    Zhou X; Jiao L; Qian Y; Dong Q; Sun Y; Zheng WV; Zhao W; Zhai W; Qiu L; Wu Y; Wang H; Gao Y; Chen J
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34068552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TIGIT in cancer immunotherapy.
    Chauvin JM; Zarour HM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor intrinsic and extrinsic immune functions of CD155.
    O'Donnell JS; Madore J; Li XY; Smyth MJ
    Semin Cancer Biol; 2020 Oct; 65():189-196. PubMed ID: 31883911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.
    Stanietsky N; Rovis TL; Glasner A; Seidel E; Tsukerman P; Yamin R; Enk J; Jonjic S; Mandelboim O
    Eur J Immunol; 2013 Aug; 43(8):2138-50. PubMed ID: 23677581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention.
    Mahnke K; Enk AH
    J Invest Dermatol; 2016 Jan; 136(1):9-11. PubMed ID: 26763417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poliovirus Receptor: More than a simple viral receptor.
    Bowers JR; Readler JM; Sharma P; Excoffon KJDA
    Virus Res; 2017 Oct; 242():1-6. PubMed ID: 28870470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.
    Chandramohan V; Bryant JD; Piao H; Keir ST; Lipp ES; Lefaivre M; Perkinson K; Bigner DD; Gromeier M; McLendon RE
    Arch Pathol Lab Med; 2017 Dec; 141(12):1697-1704. PubMed ID: 28829151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
    J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity.
    Saha S; Sparkes A; Matus EI; Lee P; Gariépy J
    Sci Rep; 2023 Mar; 13(1):4609. PubMed ID: 36944702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.
    Wang D; Gu Y; Yan X; Huo C; Wang G; Zhao Y; Teng M; Li Y
    Front Oncol; 2022; 12():844260. PubMed ID: 35433470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma).
    Sun Y; Luo J; Chen Y; Cui J; Lei Y; Cui Y; Jiang N; Jiang W; Chen L; Chen Y; Kuang Y; Tang K; Ke Z
    Int Immunopharmacol; 2020 Mar; 80():106198. PubMed ID: 31954274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TIGIT/PVR and LncRNA ANRIL dual-targetable PAMAM polymeric nanoparticles efficiently inhibited the hepatoma carcinoma by combination of immunotherapy and gene therapy.
    Wang T; Li P; Wan T; Tu B; Li J; Huang F
    J Drug Target; 2021 Aug; 29(7):783-791. PubMed ID: 33480288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.